MedPath

Moberg Pharma AB Receives Information About Clinical Cure in a Subset of Patients in the ...

Moberg Pharma AB announced lower-than-expected clinical cure rates in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus, increasing the risk of non-commercialization in the US. The study, involving 384 patients at 33 centers, is crucial for MOB-015's US registration and differs from EU-approved studies by reducing dosage. The company will await topline results before drawing conclusions.


Reference News

Moberg Pharma AB Receives Information About Clinical Cure in a Subset of Patients in the ...

Moberg Pharma AB announced lower-than-expected clinical cure rates in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus, increasing the risk of non-commercialization in the US. The study, involving 384 patients at 33 centers, is crucial for MOB-015's US registration and differs from EU-approved studies by reducing dosage. The company will await topline results before drawing conclusions.

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following ...

Moberg Pharma lowers expectations for MOB-015's clinical cure in a subset of patients in its ongoing North American Phase 3 trial, increasing the risk of non-commercialization in the US.

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following ...

Moberg Pharma AB reports lower-than-expected clinical cure rates in a subset of patients in its ongoing North American Phase 3 study for MOB-015 against nail fungus, impacting the product's commercialization risk in the US.

© Copyright 2025. All Rights Reserved by MedPath